A Multicenter Trial To Evaluate Oral Retrovir in the Treatment of Children With Symptomatic HIV Infection
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerance of oral zidovudine (AZT) when given over a period of 24
weeks to children between 3 months and 12 years of age. The effectiveness of AZT in treating
HIV infection in infants and children will also be evaluated.
HIV infection in children is most often associated with symptomatic disease and poor
prognosis. Treatment with antiviral therapy may be effective in altering the course of the
disease and decreasing mortality in these children. AZT has been shown to be effective in
certain adult patients with symptomatic HIV infection. It is therefore likely that infected
children may also benefit from this treatment.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)